Clinical trial
Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive…
NCT00441571 · Cytogen Corporation, Industry · Unknown status
Key facts
| NCT number | NCT00441571 |
|---|---|
| Title | Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer |
| Official title | A Phase 1 Study of Radiolabeled Monoclonal Antibody 7E11-C5.3(177Lu-meO-DOTA-7E11;CYT-500) in Patients With Progressive Androgen-Independent Prostate Cancer |
| Acronym | CYT-500 |
| Lead sponsor | Cytogen Corporation, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Prostate Cancer |
| Intervention type | Drug |
| Interventions | 177Lu-CYT-500 |
| Enrollment | 30 |
| Start date | Feb 1, 2007 |
| First posted | Mar 1, 2007 |
| Last update posted | Sep 10, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: